144074-96-4 Usage
Uses
Used in Pharmaceutical Industry:
Pneumocandin C(0) is used as an antifungal agent for its ability to inhibit the synthesis of β-(1,3)-D-glucan in the cell walls of fungal organisms, leading to cell lysis and death. This makes it a promising candidate for the treatment of invasive fungal infections, especially those caused by Candida and Aspergillus species.
Used in Drug Development:
Pneumocandin C(0) is utilized as a precursor in the development of antifungal drugs, such as caspofungin. Its unique antifungal properties and potential for clinical use are driving ongoing research to harness its benefits in the creation of new pharmaceutical products for the treatment of fungal infections.
Used in Research and Development:
Pneumocandin C(0) is employed as a subject of study in research aimed at understanding its antifungal properties and exploring its potential applications in medicine. This includes investigating its efficacy against various fungal species and identifying ways to optimize its use as a therapeutic agent.
Check Digit Verification of cas no
The CAS Registry Mumber 144074-96-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,4,4,0,7 and 4 respectively; the second part has 2 digits, 9 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 144074-96:
(8*1)+(7*4)+(6*4)+(5*0)+(4*7)+(3*4)+(2*9)+(1*6)=124
124 % 10 = 4
So 144074-96-4 is a valid CAS Registry Number.
InChI:InChI=1/C50H80N8O17/c1-5-25(2)18-26(3)12-10-8-6-7-9-11-13-38(66)52-32-21-36(64)47(72)56-46(71)34-20-31(62)24-58(34)50(75)40(35(63)22-37(51)65)54-48(73)41(43(68)42(67)28-14-16-29(60)17-15-28)55-45(70)33-19-30(61)23-57(33)49(74)39(27(4)59)53-44(32)69/h14-17,25-27,30-36,39-43,47,59-64,67-68,72H,5-13,18-24H2,1-4H3,(H2,51,65)(H,52,66)(H,53,69)(H,54,73)(H,55,70)(H,56,71)/t25?,26?,27-,30-,31-,32?,33+,34+,35-,36+,39+,40+,41+,42-,43?,47-/m1/s1
144074-96-4Relevant academic research and scientific papers
Stationary phases and a purification process using the stationary phases
-
Page/Page column 7-8, (2008/06/13)
This invention relates to a novel stationary phase of Formula I and a method for purifying a peptide or lipopeptide in liquid chromatography using select stationary phases, including the stationary phases of Formula I to improve the resolution and/or productivity of the purification. This chromatographic method can be used for either an analytical or preparative scale purification.
